Abstract 1358
Background
Triple drug regimens are standard of care in newly diagnosed Multiple Myeloma (MM). Studies show 4 drug regimens to be highly active. In an economically backward country like India, newer drugs and Autologous transplant may not always be feasible because of financial constraints. We studied the effect of adding Pegylated Liposomal Doxorubicin (PLD) to standard regimen on the Response Rates (RR).
Methods
60 newly diagnosed cases of MM were included in this double armed prospective, observational, comparative study. Patients were randomly assigned into 2 arms (30 Patients in each arm). Arm A consisted of VTd regimen (Inj. Bortezomib Day (D)1, D8, D15, D22 1.3mg/ / m2, Tab. Thalidomide Daily 100mg, Inj. Dexamethasone D1, D8, D15, D22 40 mg / once in 28 days). Arm B consisted of VTdD regimen (PLD D1 i.v 30mg / m2 + VTd). Hematological and biochemical parameters were noted at baseline and after completion of 4 cycles. Response assessment was done as per the criteria defined by International Myeloma Working Group (IMWG). The outcomes between the two treatment arms in terms of RR were compared.
Results
Table: 1023P
| RR | VTd | VTdD |
|---|---|---|
| Overall Response Rates | 86.6% | 93.3% |
| >very good partial response | 73.3% | 86.6% |
| Stringent Complete Response | 33.3% | 53.3% |
The differences in sCR rates were clinically very significant. However, on application of Pearson chi-square test significance p of 0.118 was seen, which maybe attributed to the lower power of the study. Poorest responses noted were highest in the 71-80 age group. Both the regimens were equally effective in ISS B patients. Neutropenia, thrombocytopenia, infections, mucositis, edema, dizzininess/somnolence and DVT were not significantly different between the two arms (P > 0.05). Palmar–plantar erythrodysesthesia (PPE) was the only new complication seen in (10%) VTdD group. Grade 3–4 toxicities were similar in both arms.
Conclusions
The role of liposomal doxorubicin in first line setting as a 4th agent along with triple drug regimen in treatment of MM looks promising, especially in countries with financial constraints for the newer drugs. Larger studies are needed to validate this.
Clinical trial identification
Legal entity responsible for the study
Scientific and Ethics Committee at HCG Hospital, Bangalore, India.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract